Stockreport

Annovis Bio: Alzheimer's Disease Topline Data Disappoints The Market [Seeking Alpha]

Annovis Bio, Inc.  (ANVS) 
PDF Topline data of AD phase II/III trial was released in a press release, and featured a small post-hoc sub-population. The stock plummeted 70% on press release announce [Read more]